[미국특허]
Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/19
A61K-031/557
출원번호
US-0905458
(2001-07-13)
발명자
/ 주소
Place, Virgil A.
Wilson, Leland F.
Doherty, Jr., Paul C.
Hanamoto, Mark S.
Spivack, Alfred P.
Gesundheit, Neil
Bennett, Sean R.
출원인 / 주소
Vivus, Inc.
대리인 / 주소
Reed, Dianne E.Reed & Eberle LLP
인용정보
피인용 횟수 :
50인용 특허 :
24
초록▼
Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators
Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.
대표청구항▼
Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators
Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided. 23:1461-1467. Amara et al., (1996) "Defining a novel cis element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 Mrna: cis-trans interactions and message stability." J. Biol. Chem. 271:20126-20131. Anazodo et al., (1995) "Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome." J. Virol. 69:1794-1801. Anazodo et al., (1996) "Relative levels of inhibition of p24 gene expression by different 20-mer antisense oligonucleotide sequences targeting nucleotides + 1129 to +1268 of the HIV-1 gag genome: An analysis of mechanism," Biochem. Biophys. Res. Commun. 229:305-309. Ashihara et al., (1979) "Cell Synchronization," Methods Enzymol., 58:248-262. Barker, R.H. Jr., et al. (1996) "Inhibition of plasmodium falciparum malaria using oligodeoxynucleotides," Proc. Natl. Acad. Sci. USA, 93(1):514-518. Bjorklund et al., (1993) "Structure and promoter characterization of the gene encoding the large subunit (R1 Protein) of mouse ribonucleotide reductase." Proc. Natl. Acad. Sci. USA, 90:11322-11326. Bjorklund, S., et al., (1990) "S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs," Biochemistry, 29(23):5452-5458. Blaesse (1997) "Gene therapy for cancer," Scientific American, 276(6):111-115. Blin et al., (1976) "A general method of isolation of high molecular weight DNA from eukaryotes," Nucleic Acids Res., 3:2303-2308. Blosmanis et al., (1987) Cancer Res., 47:1273-1277. Boven et al., (1992) "Phase II preclinical drug screening in human tumor xenografts: A first European multicenter collaborative study." Cancer Res., 52:5940-5947. Bradley et al., (1986) Proc. Natl. Acad. Sci. USA, 83:5277-5281. Branch, (1998) TIBS, 23:45-50. Brower et al. (1998) "All clear for HIV-targeting ribozyme in phase II," Nature Biotechnology, 16(2):123. Calabretta et al., (1996) "Antisense strategies in the treatment of leukemias," Semin. Oncol, 23:78. Caras, (1985) "Cloned mouse ribonucleotide reductase subunit M1 cDNA reveals amino acid sequence homology with Escherichia coli and herpes virus ribonucleotide reductases," Biol. Chem., 260:7015-7022. Chadee et al., (1995) J. Biol. Chem., 270:20098-20105. Chakrabarti, D., et al., (1993) "Cloning and characterization of subunit genes of ribonucleotide reductase, a cell-cycle-regulated enzyme, from Plasmodium falciparum," Proc. Natl. Acad. Sci. USA, 90:12020-12024. Chan et al., (1993) Biochemistry, 32:12835-12840. Chang et al., (1978) "Phenotypic expression in e. coli of a DNA sequence coding for mouse dihydrofolate reductase," Nature, 275:617-624. Chaudhuri, M.M., et al., (1992) "cDNA sequence of the small subunit of the hamster ribonucleotide reductase," Biochimica et Biophysica Acta, 1171:117-121. Chen et al., (1993) "Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: Involvement of a cis-trans interaction at the 3'-untranslated region," EMBO J., 12:3977-3986. Chen et al., (1994) "Defining a novel ribonucleotide reductase R1 mRNA cis element that binds to an unique cytoplasmic trans-acting protein," Nucleic Acids Res., 22:4796-4797. Choy et al., (1998) "Molecular mechanisms of drug resistance involving ribonucleotide reductase: Hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations," Cancer Res., 48:2029-2035. Choy et al., (1989) Biochem. Biophys. Res. Commun., 162:1417-1424. Cole et al. (1992) "Over expression of a transporter gene is a multidrug-resistant human lung cancer cell line," Science, 258:1650-1654. Cregg, J.M. et al., (1993) "Recent advances in the expression of foreign genes in pichia pastoris," Bio/Technology , 11:905-910. Crooke, (1995) "Progress in antisense therapeutics," Hematol. Pathol., 2:59-72. Damen et al., (1989) "Generation of me tasattic variants in populations of mutator and amplificator mutants," J. Natl. Cancer Inst., 81:628-631. Damen et al., (1991) "Transformation and amplification of the K-fgf Protooncogene in NIH-3T3 cells, and induction of metastatic potential, " Biochem Biophys. Acta, 1097:103-110. Davis et al., (1994) "Purification, characterization, and localization of subunit interaction area of recombinant mouse ribonucleotide reductase R1 subunit," Biol. Chem., 269:23171-23176. Devereux, J., et al., (1984) "A comprehensive set of sequence analysis programs for the VAX," Nucleic Acids Res., 12:387-395. Eckstein, (1985) "Nucleoside Phosphorothioates," Ann. Rev. Biochem. 54:367-402. Edwards, et al., (1985) Mol. Cell. Biol., 5:3280-3288. Egan, et al., (1987) "Expression of H-ras correlates with metastatic potential: Evidence for direct regulation of the metastatic phenotype in 10T1/2 and NIH 3T3 cells," Mol. Cell. Biol., 7:830-837. Egan et al., (1987) "Transformation by oncogenes encoding protein kinases induces the metastatic pheonotype." Science, 238:202-205. Eriksson et al., (1984) "Cell cycle-dependent regulation of mammalian ribonucleotide reductase: The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis," J. Biol. Chem. 259:11695-11700. Fan et al., (1996) "Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential," , 93:14036-1404. Fan et al., (1996) "A link between ferritin gene expression and ribonucleotide reductase R2 protein, as demonstrated by retroviral mediated expression of R2 cDNA," FEBS Lett. 382:145-148. Fan et al., (1997) "The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments," Proc. Natl. Acad. Sci. USA, 94:13181-13186. Felgner (1997) "Nonviral strategies for gene therapy," Scientific American. Jun., 1997, pp. 102-106. Flintoff (1989) Methotrexate, In: Gupta, R.S. (ed.), Drug Resistance in Mammalian Cells, Boca Raton, Florida: CRC Press, Inc., pp. 1-14. Flory, C.M., et al., (1996) "Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint," Proc. Natl. Acad. Sci. USA, 93:754-758. Fujita et al., (1980) "Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient," Journal of Surgical Oncology, 15:211-219. Fujita et al., (1982) "Application of nude mouse-human cancer xenograft systems for sensitivity test of anticancer drugs," Gan to Kagaku Ryoho, 9(4):606-615 (English Abstract). Fujita et al., (1984) "Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect," Gan No Rinsho 30(9 Supp): 1168-1174 (English abstract). Fujita et al., (1991) "Predictability of preclinical evaluation of anticancer drugs by human gastrointestinal cancer-nude mouse panel," Gan To Kagaku Ryohyo, 18(9):1429-1437 (English abstract). Furukawa et al., (1993) "Orthotopic transplantation of histoligically intact clinical specimens of stomach cancer to nude mice: Correlation of metastic sites in mouse and individual patient donors," Int. J. Cancer, 53:608-612. Gannon et al., (1990) "Activating mutations in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form," EMBO J., 9:1595-1602. Gerwitz, (1993) "Oligodeoxynucleotide-based therapeutics for human leukemias," Stem. Cells. Dayt., 11:96-103. Gerwitz et al., (1996) Proc. Natl. Acad. Sci. USA, 93:3161-3163. Gilboa et al., (1986) "Transfer and expression of cloned genes using retroviral vectors," BioTechniques, 4(6):504-512. Giovanella et al., (1983) "Correlation between response to chemotherapy of human tumors in patients and in nude mice," Cancer, 52:1146-1152. Good et al., (1998) "Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA," Proc. Natl. Acad. Sci. USA, 95:2073-2076. Gregg, et al., (1993) Recent Advances in the Expression of Foreign Genes in Pichia pastoris, Bio/Technology, 11:905-910. Greene, L.A.., et al., (1976) "Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor," Proc. Natl. Acad. Sci. USA, 73(7):2424-2428. Gubler, U., et al.,(1983) "A simple and very efficient method for generating cDNA libraries," Gene, 25:263-269. Gupta, R.S. (ed.), Drug Resistance in mammalian Cells, vol. 1 (1989), CRC Press, Boca Raton, Florida: pp. 15-27. Gura, (1977) Science, 278:1041-1042. Hampel et al., (1989) "RNA catalytic properties of the minimum (-) sTRSV sequence," Biochemistry, 28:4929-4933. Hanania et al.,(1995) "Recent advances in the application of gene therapy to human disease," Am. J. Med., 99:537-552. Hards et al., (1981) "N-carbamoyloxyurea-resistant Chinese hamster ovary cells with elevated levels of ribonucleotide reductase activity," J. Cell. Physiol., 106-309-319. Huang, A., et al., (1994) "Fibroblast growth factor mediated alterations in drug resistance and evidence of gene amplification," Oncongene, 9:491-499. Huang, A. et al., (1995) "Drug resistance and gene amplification potential regulated by transforming growth factor beta1gene expression," Cancer Res., 55:1758-1762. Huang, A., et al., (1995) "Multiple effects on drug sensitivity, genome stability and malignant potential by combinations of H-ras, c-myc and mutant p53 gene overexpression," Ind. J. Oncol. 7:57-63. Huang, A., et al., "Ribonucleotide reductase R2 gene expression and changes in durg sensitivity and genome stability," Cancer Research, 57:4876-4881. Hunter (1995) "Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling," Cell, 80:225-236. Hurta et al., (1991) "Early induction of ribonucleotide reductase gene expression by transforming growth factor beta1in malignant H-ras transformed cell lines," J. Biol. Chem., 266(35):24097-24100. Hurta et al., (1992) "Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent," J. Biol. Chem., 267:7066-7071. Hurta et al., (1994)J. Cell Physiol., 158:187-197. Hurta et al., (1995) "Malignant transformation by H-ras results in aberrant regulation of ribonucleotide reductase gene expression by transforming growth factor beta1", J. Cell. Biochem., 57:543-556. Iyer et al. (1990) "The automated synthesis of sulfer-containing oligodeoxyribonucleotides using 3-II-1, 2-Benzodithiol-3-one 1, 1-Dioxide as a sulfer-transfer reagent," J. Org. Chem., 55:4693-4699. Jelinek et al., (1994) Mol. Cell. Biol., 14:8212-8218. Jensen et al., (1994) "Identification of genes expressed in premalignant breast disease by microscopy-directed cloning," Proc. Natl. Acad. Sci. USA, 91:9257-9261. Kern et al., (1992) "Oncogenic forms of p53 inhibit p53-regulated gene expression." Science, 256:827-830. Kijima et al., H., et al., (1995) "Therapeutic applications of ribozymes," Pharmac. Ther., 68(2):247-267. Kohn (1996) "Regulartory genes and drug sensitivity," J. Natl. Cancer Inst., 88:1255-1256. Koong et al., (1994) Cancer Res., 54:5273-5279. L'Huillier, P.J. et al., (1996) "Efficacy of hammerhead ribozymes targeting alpha-lactalbumin transcripts: Experiments in cells and transgenic mine," Nucleic Acids and Molecular Biology, 10:283-300. Larsson, S., et al., (1994) "Reduced beta2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme," Nucleic Acids Research, 22(12):2242-2248. Leevers et al., (1994) Nature, 369:411-414. Lefebvre-D'Hellencourt et al., (1995) "Immunomodulation by cytokine antisense oligonucleotides," Eur. Cytokine Netw. 6:7-19. Lenormand et al., (1996) J. Biol. Chem., 271:15762-15768. Lescure et al., (1994) "Preparation and characterization of novel poly(methyoidene ma
Skuballa Werner (Berlin DEX) Raduechel Bernd (Berlin DEX) Schwarz Norbert (Berlin DEX) Vorbrueggen Helmut (Berlin DEX) Elger Walter (Berlin DEX) Loge Olaf (Berlin DEX) Town Michael-Harold (Berlin DEX, 9-Fluoroprostaglandin derivatives, and use as medicinal agents.
Van Lommen Guy R. E. (Berlaar BEX) De Bruyn Marcel F. L. (Hoogstraten BEX) Schroven Marc F. J. (Heist Op Den Berg BEX), Derivatives of 2,2′-iminobisethanol.
Gioco Diane-Marie (West Haven CT) Zorgniotti ; deceased Adrian (late of Wyland MA by Flavia Zorgniotti ; executrix ), Methods for modulating the human sexual response.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Verhoef, Erik T.; DiPerna, Paul M.; Rosinko, Mike; Williamson, Mark; Kruse, Geoffrey A.; Ulrich, Thomas R.; Lamb, Phil; Saint, Sean; Michaud, Michael; Trevaskis, William, Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Tuiten, Jan Johan Adriaan; Bloemers, Johannes Martinus Maria, Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction.
St. Anne, Cora; St. Anne, Joseph; Santa Cruz, Cindy; Benderev, Theodore V.; Willis, Eric; Wasserstein, Kevin, Systems and methods for treating female incontinence and pelvic nerve dysfunction.
Tuiten, Jan Johan Adriaan; Bloemers, Johannes Martinus Maria; De Lange, Robertus Petrus Johannes, Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction.
Tuiten, Jan Johan Adriaan; Bloemers, Johannes Martinus Maria; De Lange, Robertus Petrus Johannes, Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.